CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015-Still in the Ballpark

被引：11

作者：

Narod, Steven A. ^{[1
]}

Dent, Rebecca A. ^{[2
]}

Foulkes, William D. ^{[3
,4
]}

机构：

[1] Womens Coll Res Inst, Familial Breast Canc Res Unit, Toronto, ON, Canada

[2] Sunnybrook Hlth Sci Ctr, Dept Med Oncol, Toronto, ON M4N 3M5, Canada

[3] McGill Univ, Jewish Gen Hosp, Dept Human Genet, Montreal, PQ H3T 1E2, Canada

[4] McGill Univ, McGill Univ Hlth Ctr, Montreal, PQ H3T 1E2, Canada

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 17期

关键词：

NEOADJUVANT CISPLATIN; MUTATIONS;

D O I：

10.1158/1078-0432.CCR-14-3122

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The research article by Dent and colleagues, which was published in the August 1, 2007, issue of Clinical Cancer Research, provided a clinical description of metastatic progression of triple-negative breast cancers. Finding successful treatment strategies for women with triple-negative breast cancer remains a challenge. (C) 2015 AACR.

引用

页码：3813 / +

页数：2

共 50 条

[21] CCR 20th Anniversary Commentary: BMS-247550-Microtubule Stabilization as Successful Targeted Therapy
Pabla, Navjotsingh
Sparreboom, Alex
CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1237 - 1239
[22] CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib-A Look Back
Mendel, Dirk B.
Cherrington, Julie M.
Laird, A. Douglas
CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2415 - 2417
[23] CCR 20th Anniversary Commentary: Chimeric Antigen Receptors-From Model T to the Tesla
Hwu, Patrick
CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3099 - 3101
[24] CCR 20th Anniversary Commentary: In Search of Cetuximab's First Indication-Combination Therapy with Irinotecan in Colorectal Cancer
Hicklin, Daniel J.
CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1505 - 1507
[25] CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux
Davar, Diwakar
Kirkwood, John M.
CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5412 - 5414
[26] CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer-From Concept to Practice
Camp, E. Ramsay
Ellis, Lee M.
CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3578 - 3580
[27] Significance of the monocyte CCR2-CCL2 axis in triple-negative breast cancer
Budzyn, Magdalena
Kubicka, Agata
Kaja, Elzbieta
Kycler, Witold
Zaluska-Kusz, Joanna
Brzezinski, Jacek J.
Sperling, Marcelina
Bukowska, Alicja
Grupinska, Joanna
ARCHIVES OF MEDICAL RESEARCH, 2025, 56 (05)
[28] CDC20 is a novel therapeutic target in triple-negative breast cancer
Sharma, Jayesh K.
Alluri, Prasanna
Udden, Nashir
CANCER RESEARCH, 2020, 80 (16)
[29] CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth
Mendelsohn, John
Prewett, Marie
Rockwell, Patricia
Goldstein, Neil I.
CLINICAL CANCER RESEARCH, 2015, 21 (02) : 227 - 229
[30] The Proteomic Landscape of Triple-Negative Breast Cancer (vol 11, pg 630, 2015)
Lawrence, Robert T.
Perez, Elizabeth M.
Hernandez, Daniel
Miller, Chris P.
Haas, Kelsey M.
Irie, Hanna Y.
Lee, Su-In
Blau, C. Anthony
Villen, Judit
CELL REPORTS, 2015, 11 (06): : 990 - 990

← 1 2 3 4 5 →